Trial · NCT00880906
Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
NCT00880906, Not applicable, Completed, Vanderbilt University; results first posted 2014-05-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis. Trials, record NCT00880906. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00880906
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
- NCT number
- NCT00880906
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 50 participants, actual
- Lead sponsor
- Vanderbilt University
- Conditions
- Suspected Eosinophilic Esophagitis
- Interventions
- Esophageal dilation, Steroid and Proton Pump Inhibitor Therapy
- First posted
- 2009-04-14
- Last updated
- 2017-11-06
- Results first posted
- 2014-05-26
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) | 60 days | Dysphagia Scores: 0 = able to eat normal diet / no dysphagia. 1. = able to swallow some solid foods 2. = able to swallow only semi solid foods 3. = able to swallow liquids only 4. = unable to swallow anything / total dysphagia |
| Secondary | Immunological Assessment Into the Etiology of Eosinophilic Esophagitis | 60 days |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) | 60 days | Percent Change | NUMBER | |
| SECONDARY | Immunological Assessment Into the Etiology of Eosinophilic Esophagitis | 60 days | Saved samples were not analyzed due to there being no difference in the primary outcome measure. |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) | Group A Receives Routine Care and Esophageal Dilatation | 69 | Percent Change | ||
| Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) | Group B Receives SOC Only | 79 | Percent Change |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A Drug Therapy Plus Dilation | 29 | |
| Overall Study | STARTED | Group B Drug Therapy Only | 21 | |
| Overall Study | COMPLETED | Group A Drug Therapy Plus Dilation | 17 | |
| Overall Study | COMPLETED | Group B Drug Therapy Only | 14 | |
| Overall Study | NOT COMPLETED | Group A Drug Therapy Plus Dilation | 12 | |
| Overall Study | NOT COMPLETED | Group B Drug Therapy Only | 7 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A Receives Routine Care and Esophageal Dilatation | ||
| Total, all-cause mortality | Group B Receives SOC Only | ||
| Total, other adverse events | Group A Receives Routine Care and Esophageal Dilatation | 0 | 17 |
| Total, other adverse events | Group B Receives SOC Only | 0 | 14 |
| Total, serious adverse events | Group A Receives Routine Care and Esophageal Dilatation | 0 | 17 |
| Total, serious adverse events | Group B Receives SOC Only | 0 | 14 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Group A Receives Routine Care and Esophageal Dilatation vs Group B Receives SOC Only: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00880906
GET https://conductscience.org/api/trials/v1/NCT00880906/registered